Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Edurne, Mugarza"'
Autor:
Panayiotis Anastasiou, Christopher Moore, Sareena Rana, Mona Tomaschko, Claire E. Pillsbury, Andrea de Castro, Jesse Boumelha, Edurne Mugarza, Sophie de Carné Trécesson, Ania Mikolajczak, Cristina Blaj, Robert Goldstone, Jacqueline A. M. Smith, Elsa Quintana, Miriam Molina-Arcas, Julian Downward
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-17 (2024)
Abstract Mutant selective drugs targeting the inactive, GDP-bound form of KRASG12C have been approved for use in lung cancer, but resistance develops rapidly. Here we use an inhibitor, (RMC-4998) that targets RASG12C in its active, GTP-bound form, to
Externí odkaz:
https://doaj.org/article/f04ce583c0fc4b438b6298469e1bd117
Autor:
Sameeha Jilani, Justin D. Saco, Edurne Mugarza, Aleida Pujol-Morcillo, Jeffrey Chokry, Clement Ng, Gabriel Abril-Rodriguez, David Berger-Manerio, Ami Pant, Jane Hu, Rubi Gupta, Agustin Vega-Crespo, Ignacio Baselga-Carretero, Jia M. Chen, Daniel Sanghoon Shin, Philip Scumpia, Roxana A. Radu, Yvonne Chen, Antoni Ribas, Cristina Puig-Saus
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-19 (2024)
Abstract A major limitation to developing chimeric antigen receptor (CAR)-T cell therapies for solid tumors is identifying surface proteins highly expressed in tumors but not in normal tissues. Here, we identify Tyrosinase Related Protein 1 (TYRP1) a
Externí odkaz:
https://doaj.org/article/cd2701d25f8e48e2a9b53f8ebd1a39b3
Autor:
Febe van Maldegem, Karishma Valand, Megan Cole, Harshil Patel, Mihaela Angelova, Sareena Rana, Emma Colliver, Katey Enfield, Nourdine Bah, Gavin Kelly, Victoria Siu Kwan Tsang, Edurne Mugarza, Christopher Moore, Philip Hobson, Dina Levi, Miriam Molina-Arcas, Charles Swanton, Julian Downward
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
The tumour microenvironment (TME) may change in response to cancer treatments such as KRAS G12C inhibition, with potential implications for combination therapies. Here, the authors provide an antibody panel and workflow for analysing the TME with ima
Externí odkaz:
https://doaj.org/article/c85c11c742864408a99b5e94e13e53db
Autor:
Jesse Boumelha, Sophie de Carné Trécesson, Emily K. Law, Pablo Romero-Clavijo, Matthew A. Coelho, Kevin W. Ng, Edurne Mugarza, Christopher Moore, Sareena Rana, Deborah R. Caswell, Miguel Murillo, David C. Hancock, Prokopios P. Argyris, William L. Brown, Cameron Durfee, Lindsay K. Larson, Rachel I. Vogel, Alejandro Suárez-Bonnet, Simon L. Priestnall, Philip East, Sarah J. Ross, George Kassiotis, Miriam Molina-Arcas, Charles Swanton, Reuben Harris, Julian Downward
Publikováno v:
Cancer Res
Mutations in oncogenes such as KRAS and EGFR cause a high proportion of lung cancers. Drugs targeting these proteins cause tumor regression but ultimately fail to elicit cures. As a result, there is an intense interest in how to best combine targeted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::128d1ca05f75d8769b0a636c3c99db68
https://doi.org/10.1158/0008-5472.can-22-0325
https://doi.org/10.1158/0008-5472.can-22-0325
Autor:
Jesse Boumelha, Andrea de Castro, Nourdine Bah, Hongui Cha, Sophie de Carné Trécesson, Sareena Rana, Panayiotis Anastasiou, Edurne Mugarza, Christopher Moore, Robert Goldstone, Phil East, Kevin Litchfield, Se-Hoon Lee, Miriam Molina-Arcas, Julian Downward
Oncogenic KRAS impairs anti-tumour immune responses, but effective strategies to combine KRAS inhibitors and immunotherapies have so far proven elusive. In vivo CRISPR-Cas9 screening in an immunogenic murine lung cancer model identifies mechanisms by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4c672d746fcfa1e56f0135765efec632
https://doi.org/10.1101/2023.04.13.536740
https://doi.org/10.1101/2023.04.13.536740
Autor:
Julian Downward, Reuben Harris, Charles Swanton, Miriam Molina-Arcas, George Kassiotis, Sarah J. Ross, Philip East, Simon L. Priestnall, Alejandro Suárez-Bonnet, Rachel I. Vogel, Lindsay K. Larson, Cameron Durfee, William L. Brown, Prokopios P. Argyris, David C. Hancock, Miguel Murillo, Deborah R. Caswell, Sareena Rana, Christopher Moore, Edurne Mugarza, Kevin W. Ng, Matthew A. Coelho, Pablo Romero-Clavijo, Emily K. Law, Sophie de Carné Trécesson, Jesse Boumelha
Supplementary Data from An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55fc3e20f035a7d1519858bb7c34e1ae
https://doi.org/10.1158/0008-5472.22432362
https://doi.org/10.1158/0008-5472.22432362
Autor:
Julian Downward, Reuben Harris, Charles Swanton, Miriam Molina-Arcas, George Kassiotis, Sarah J. Ross, Philip East, Simon L. Priestnall, Alejandro Suárez-Bonnet, Rachel I. Vogel, Lindsay K. Larson, Cameron Durfee, William L. Brown, Prokopios P. Argyris, David C. Hancock, Miguel Murillo, Deborah R. Caswell, Sareena Rana, Christopher Moore, Edurne Mugarza, Kevin W. Ng, Matthew A. Coelho, Pablo Romero-Clavijo, Emily K. Law, Sophie de Carné Trécesson, Jesse Boumelha
Supplementary Table from An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5646e5b6edd1bf21906dd5a24045f7ea
https://doi.org/10.1158/0008-5472.22432356.v1
https://doi.org/10.1158/0008-5472.22432356.v1
Autor:
Edurne Mugarza, Febe van Maldegem, Jesse Boumelha, Christopher Moore, Sareena Rana, Miriam Llorian Sopena, Philip East, Rachel Ambler, Panayiotis Anastasiou, Pablo Romero-Clavijo, Karishma Valand, Megan Cole, Miriam Molina-Arcas, Julian Downward
Publikováno v:
Science Advances, 8(29):eabm8780. American Association for the Advancement of Science
Mugarza, E, van Maldegem, F, Boumelha, J, Moore, C, Rana, S, Llorian Sopena, M, East, P, Ambler, R, Anastasiou, P, Romero-Clavijo, P, Valand, K, Cole, M, Molina-Arcas, M & Downward, J 2022, ' Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers ', Science Advances, vol. 8, no. 29, eabm8780, pp. eabm8780 . https://doi.org/10.1126/sciadv.abm8780
Mugarza, E, van Maldegem, F, Boumelha, J, Moore, C, Rana, S, Llorian Sopena, M, East, P, Ambler, R, Anastasiou, P, Romero-Clavijo, P, Valand, K, Cole, M, Molina-Arcas, M & Downward, J 2022, ' Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers ', Science Advances, vol. 8, no. 29, eabm8780, pp. eabm8780 . https://doi.org/10.1126/sciadv.abm8780
Recently developed KRAS G12C inhibitory drugs are beneficial to lung cancer patients harboring KRAS G12C mutations, but drug resistance frequently develops. Because of the immunosuppressive nature of the signaling network controlled by oncogenic KRAS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2eba7ee317fefd79fc260d98ab44b82c
https://research.vumc.nl/en/publications/8bed69b7-11f1-4db0-bb5b-f054048a8ab8
https://research.vumc.nl/en/publications/8bed69b7-11f1-4db0-bb5b-f054048a8ab8
Autor:
Edurne, Mugarza, Febe, van Maldegem, Jesse, Boumelha, Christopher, Moore, Sareena, Rana, Miriam, Llorian Sopena, Philip, East, Rachel, Ambler, Panayiotis, Anastasiou, Pablo, Romero-Clavijo, Karishma, Valand, Megan, Cole, Miriam, Molina-Arcas, Julian, Downward
Publikováno v:
Science advances. 8(29)
Recently developed KRAS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cd6d4ef021b1fc55cccd62a3fc557b83
https://pubmed.ncbi.nlm.nih.gov/35857848
https://pubmed.ncbi.nlm.nih.gov/35857848
Autor:
Megan Cole, Jesse Boumelha, Miriam Llorian Sopena, Miriam Molina-Arcas, Panos Anastasiou, Sareena Rana, Christopher I. Moore, Febe van Maldegem, Philip East, Julian Downward, Edurne Mugarza, Karishma Valand, Pablo Romero Clavijo, Rachel Ambler
The recent development and approval of KRASG12C inhibitors promises to change profoundly the clinical management of lung cancer patients harbouring KRASG12C mutations. However, early clinical data indicate that acquired drug resistance can frequently
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eebd4728b44a095dd96a3a4fd4745a56
https://doi.org/10.1101/2021.10.18.464819
https://doi.org/10.1101/2021.10.18.464819